{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:04:46Z","timestamp":1747368286671,"version":"3.40.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-024-11289-z","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:07:39Z","timestamp":1734635259000},"page":"3476-3485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Muscle atrophy and organ enlargement associated with quality of life during systemic therapy for melanoma: findings from an AI-based body composition analysis"],"prefix":"10.1007","volume":"35","author":[{"given":"Itske","family":"Fraterman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Estacio","family":"Cerquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly M.","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"van der Loo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Wilgenhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lonneke V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina G. H.","family":"Beets-Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud L. M.","family":"Tissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-289X","authenticated-orcid":false,"given":"Stefano","family":"Trebeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"11289_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535\u20131546","journal-title":"N Engl J Med"},{"key":"11289_CR2","doi-asserted-by":"crossref","unstructured":"Larkin J, Del Vecchio M, Mandala M et al (2023) Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res 29:3352\u20133361","DOI":"10.1158\/1078-0432.CCR-22-3145"},{"key":"11289_CR3","doi-asserted-by":"publisher","unstructured":"Eggermont AM, Blank CU, Mandal\u00e0 M et al (2020) Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG\/Keynote 054 double-blinded phase III trial at three-year median follow-up. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.10000","DOI":"10.1200\/JCO.2020.38.15_suppl.10000"},{"key":"11289_CR4","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M et al (2020) Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. J Clin Oncol 38:3925\u20133936","journal-title":"J Clin Oncol"},{"key":"11289_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824\u20131835","journal-title":"N Engl J Med"},{"key":"11289_CR6","doi-asserted-by":"crossref","unstructured":"Robert C, Carlino MS, McNeil C et al (2023) Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol 41:3998\u20134003","DOI":"10.1200\/JCO.22.01599"},{"key":"11289_CR7","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D et al (2018) Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol 36:3441\u20133449","journal-title":"J Clin Oncol"},{"key":"11289_CR8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813\u20131823","journal-title":"N Engl J Med"},{"key":"11289_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238","journal-title":"Ann Oncol"},{"key":"11289_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103919","volume":"183","author":"MD Egeler","year":"2023","unstructured":"Egeler MD, van Leeuwen M, Fraterman I et al (2023) Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: a systematic scoping review. Crit Rev Oncol Hematol 183:103919","journal-title":"Crit Rev Oncol Hematol"},{"key":"11289_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","volume":"60","author":"AH Boekhout","year":"2021","unstructured":"Boekhout AH, Rogiers A, Jozwiak K et al (2021) Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. Acta Oncol 60:69\u201377","journal-title":"Acta Oncol"},{"key":"11289_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5269062","volume":"2019","author":"A Rogiers","year":"2019","unstructured":"Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B (2019) Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol 2019:5269062","journal-title":"J Oncol"},{"key":"11289_CR13","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/cam4.5183","volume":"12","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Qin YR (2023) Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: a systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. Cancer Med 12:2262\u20132280","journal-title":"Cancer Med"},{"key":"11289_CR14","doi-asserted-by":"crossref","unstructured":"Garutti M, Bonin S, Buriolla S et al (2021) Find the flame: predictive biomarkers for immunotherapy in melanoma. Cancers (Basel) 13:1819","DOI":"10.3390\/cancers13081819"},{"key":"11289_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00209-0","volume":"8","author":"R Bai","year":"2020","unstructured":"Bai R, Lv Z, Xu D, Cui J (2020) Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 8:34","journal-title":"Biomark Res"},{"key":"11289_CR16","doi-asserted-by":"publisher","first-page":"9539","DOI":"10.1200\/JCO.2022.40.16_suppl.9539","volume":"40","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Dimitriadis P, Rozeman EA et al (2022) The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI)\u2009+\u2009nivolumab (NIVO) in stage III melanoma. J Clin Oncol 40:9539","journal-title":"J Clin Oncol"},{"key":"11289_CR17","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U (2019) clinicalguidelines@esmo.org EGCEa. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 30:1884\u20131901","journal-title":"Ann Oncol"},{"key":"11289_CR18","doi-asserted-by":"crossref","unstructured":"Fraterman I, Reijers ILM, Dimitriadis P et al (2023) Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma. Nat Med 29:3090\u20133099","DOI":"10.1038\/s41591-023-02631-x"},{"key":"11289_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"11289_CR20","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","volume":"123","author":"K Cooper","year":"2020","unstructured":"Cooper K, Tappenden P, Cantrell A, Ennis K (2020) A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. Br J Cancer 123:1686\u20131696","journal-title":"Br J Cancer"},{"key":"11289_CR21","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","volume":"122","author":"L Belin","year":"2020","unstructured":"Belin L, Tan A, De Rycke Y, Dechartres A (2020) Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review. Br J Cancer 122:1707\u20131714","journal-title":"Br J Cancer"},{"key":"11289_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113601","volume":"200","author":"M Egeler","year":"2024","unstructured":"Egeler M, Lai-Kwon J, Tissier R et al (2024) Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy. Eur J Cancer 200:113601","journal-title":"Eur J Cancer"},{"key":"11289_CR23","doi-asserted-by":"publisher","first-page":"12861","DOI":"10.1002\/cam4.5967","volume":"12","author":"EL Looman","year":"2023","unstructured":"Looman EL, Cheng PF, Lai-Kwon J et al (2023) Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors. Cancer Med 12:12861\u201312873","journal-title":"Cancer Med"},{"key":"11289_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/RLI.0000000000001040","volume":"59","author":"J Haubold","year":"2024","unstructured":"Haubold J, Baldini G, Parmar V et al (2024) BOA: a CT-based body and organ analysis for radiologists at the point of care. Invest Radiol 59:433\u2013441. https:\/\/doi.org\/10.1097\/RLI.0000000000001040","journal-title":"Invest Radiol"},{"key":"11289_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"11289_CR26","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.230024","volume":"5","author":"J Wasserthal","year":"2023","unstructured":"Wasserthal J, Breit HC, Meyer MT et al (2023) TotalSegmentator: robust segmentation of 104 anatomic structures in CT images. Radiol Artif Intell 5:e230024","journal-title":"Radiol Artif Intell"},{"key":"11289_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00330-014-3408-2","volume":"25","author":"E Pompe","year":"2015","unstructured":"Pompe E, Willemink MJ, Dijkhuis GR et al (2015) Intravenous contrast injection significantly affects bone mineral density measured on CT. Eur Radiol 25:283\u2013289. https:\/\/doi.org\/10.1007\/s00330-014-3408-2","journal-title":"Eur Radiol"},{"key":"11289_CR28","unstructured":"Team RC (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. http:\/\/www.R-project.org\/"},{"key":"11289_CR29","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1148\/rg.220056","volume":"42","author":"K Ozaki","year":"2022","unstructured":"Ozaki K, Higuchi S, Kimura H, Gabata T (2022) Liver metastases: correlation between imaging features and pathomolecular environments. Radiographics 42:1994\u20132013","journal-title":"Radiographics"},{"key":"11289_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4236\/ss.2012.33025","volume":"3","author":"D Elias","year":"2012","unstructured":"Elias D, Maggiori L, Misitano P et al (2012) Volumetric modifications of metastatic liver volumes after dramatic responses under chemotherapy. Surg Sci 3:126\u2013130","journal-title":"Surg Sci"},{"key":"11289_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10238-015-0353-6","volume":"16","author":"I Giannini","year":"2016","unstructured":"Giannini I, Cutrignelli DA, Resta L, Gentile A, Vincenti L (2016) Metastatic melanoma of the gallbladder: report of two cases and a review of the literature. Clin Exp Med 16:295\u2013300","journal-title":"Clin Exp Med"},{"key":"11289_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/1097-0142(19870701)60:1<100::AID-CNCR2820600118>3.0.CO;2-9","volume":"60","author":"B Klein","year":"1987","unstructured":"Klein B, Stein M, Kuten A et al (1987) Splenomegaly and solitary spleen metastasis in solid tumors. Cancer 60:100\u2013102","journal-title":"Cancer"},{"key":"11289_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11558-y","volume":"23","author":"V Aslan","year":"2023","unstructured":"Aslan V, Karab\u00f6rk K\u0131l\u0131\u00e7 AC et al (2023) The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma. BMC Cancer 23:1045","journal-title":"BMC Cancer"},{"key":"11289_CR34","doi-asserted-by":"crossref","unstructured":"Duwe G, M\u00fcller L, Ruckes C et al (2023) Change in splenic volume as a surrogate marker for immunotherapy response in patients with advanced urothelial and renal cell carcinoma-evaluation of a novel approach of fully automated artificial intelligence based splenic segmentation. Biomedicines 11:2482","DOI":"10.3390\/biomedicines11092482"},{"key":"11289_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2217\/imt-2021-0022","volume":"13","author":"L Susok","year":"2021","unstructured":"Susok L, Reinert D, Lukas C, Stockfleth E, Gambichler T (2021) Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade. Immunotherapy 13:885\u2013891","journal-title":"Immunotherapy"},{"key":"11289_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00520-019-04818-w","volume":"28","author":"A O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly A, Hughes P, Mann J et al (2020) An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support Care Cancer 28:561\u2013570","journal-title":"Support Care Cancer"},{"key":"11289_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:1071\u20131077","journal-title":"Invest New Drugs"},{"key":"11289_CR38","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"11289_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0604-2","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tran CN, Ge PS et al (2019) Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 7:118. https:\/\/doi.org\/10.1186\/s40425-019-0604-2","journal-title":"J Immunother Cancer"},{"key":"11289_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2022.100434","volume":"9","author":"B Gosangi","year":"2022","unstructured":"Gosangi B, McIntosh L, Keraliya A et al (2022) Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open 9:100434","journal-title":"Eur J Radiol Open"},{"key":"11289_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133207","volume":"14","author":"AM Berz","year":"2023","unstructured":"Berz AM, Boughdad S, Vietti-Violi N et al (2023) Imaging assessment of toxicity related to immune checkpoint inhibitors. Front Immunol 14:1133207","journal-title":"Front Immunol"},{"key":"11289_CR42","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","volume":"15","author":"M Biewenga","year":"2021","unstructured":"Biewenga M, van der Kooij MK, Wouters M et al (2021) Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatol Int 15:510\u2013519","journal-title":"Hepatol Int"},{"key":"11289_CR43","first-page":"195","volume":"19","author":"WK Neto","year":"2020","unstructured":"Neto WK, Soares EG, Vieira TL et al (2020) Gluteus maximus activation during common strength and hypertrophy exercises: a systematic review. J Sports Sci Med 19:195\u2013203","journal-title":"J Sports Sci Med"},{"key":"11289_CR44","first-page":"Cd011292","volume":"1","author":"IM Lahart","year":"2018","unstructured":"Lahart IM, Metsios GS, Nevill AM, Carmichael AR (2018) Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev 1:Cd011292","journal-title":"Cochrane Database Syst Rev"},{"key":"11289_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/bjsports-2017-097891","volume":"52","author":"MG Sweegers","year":"2018","unstructured":"Sweegers MG, Altenburg TM, Chinapaw MJ et al (2018) Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. Br J Sports Med 52:505\u2013513","journal-title":"Br J Sports Med"},{"key":"11289_CR46","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.amepre.2012.04.027","volume":"43","author":"TW Puetz","year":"2012","unstructured":"Puetz TW, Herring MP (2012) Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. Am J Prev Med 43:e1\u2013e24","journal-title":"Am J Prev Med"},{"key":"11289_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/328636","volume":"2015","author":"JF Meneses-Ech\u00e1vez","year":"2015","unstructured":"Meneses-Ech\u00e1vez JF, Gonz\u00e1lez-Jim\u00e9nez E, Ram\u00edrez-V\u00e9lez R (2015) Effects of supervised multimodal exercise interventions on cancer-related fatigue: systematic review and meta-analysis of randomized controlled trials. Biomed Res Int 2015:328636","journal-title":"Biomed Res Int"},{"key":"11289_CR48","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","volume":"51","author":"KL Campbell","year":"2019","unstructured":"Campbell KL, Winters-Stone KM, Wiskemann J et al (2019) Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc 51:2375\u20132390","journal-title":"Med Sci Sports Exerc"},{"key":"11289_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2022.111829","volume":"105","author":"Y Deng","year":"2023","unstructured":"Deng Y, Zhao L, Huang X, Zeng Y, Xiong Z, Zuo M (2023) Contribution of skeletal muscle to cancer immunotherapy: a focus on muscle function, inflammation, and microbiota. Nutrition 105:111829","journal-title":"Nutrition"},{"key":"11289_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.03.039","volume":"170","author":"A Machingura","year":"2022","unstructured":"Machingura A, Taye M, Musoro J et al (2022) Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: validation study. Eur J Cancer 170:1\u20139","journal-title":"Eur J Cancer"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11289-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11289-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11289-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:08:08Z","timestamp":1747307288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11289-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["11289"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11289-z","relation":{},"ISSN":["1432-1084"],"issn-type":[{"type":"electronic","value":"1432-1084"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Stefano Trebeschi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"R.G.H.B.-T. is a member of the Scientific Editorial Board for European Radiology (section: oncology). As such they have not participated in the selection nor review processes for this article. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}